|
Magnetic-Resonance-Guided Radiofrequency Ablation in Treating Patients With Primary Kidney Cancer, Liver Metastases, or Other Solid Tumors Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Magnetic-Resonance-Guided Radiofrequency Ablation in Treating Patients With Primary Kidney Cancer, Liver Metastases, or Other Solid Tumors conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Magnetic-Resonance-Guided Radiofrequency Ablation in Treating Patients With Primary Kidney Cancer, Liver Metastases, or Other Solid Tumors Clinical research trials and Magnetic-Resonance-Guided Radiofrequency Ablation in Treating Patients With Primary Kidney Cancer, Liver Metastases, or Other Solid Tumors medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Magnetic-Resonance-Guided Radiofrequency Ablation in Treating Patients With Primary Kidney Cancer, Liver Metastases, or Other Solid Tumors. Magnetic-Resonance-Guided Radiofrequency Ablation in Treating Patients With Primary Kidney Cancer, Liver Metastases, or Other Solid Tumors Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Magnetic-Resonance-Guided Radiofrequency Ablation in Treating Patients With Primary Kidney Cancer, Liver Metastases, or Other Solid Tumors clinical trial. Subjects often receive the most expert healthcare possible for their Magnetic-Resonance-Guided Radiofrequency Ablation in Treating Patients With Primary Kidney Cancer, Liver Metastases, or Other Solid Tumors condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > Magnetic-Resonance-Guided Radiofrequency Ablation in Treating Patients With Primary Kidney Cancer, Liver Metastases, or Other Solid Tumors  Magnetic-Resonance-Guided Radiofrequency Ablation in Treating Patients With Primary Kidney Cancer, Liver Metastases, or Other Solid Tumors
Magnetic-Resonance-Guided Radiofrequency Ablation in Treating Patients With Primary Kidney Cancer, Liver Metastases, or Other Solid Tumors
For Condition: stage 4 renal cell cancer,stage 3 renal cell cancer,recurrent renal cell cancer,unspecified adult solid tumor, protocol specific,liver metastases
Status: Recruiting
Sponsor(s): Ireland Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Radiofrequency ablation uses high-frequency electric current to heat and kill tumor cells. Magnetic resonance imaging-guided radiofrequency ablation may an effective treatment for primary kidney cancer, liver metastases, or other solid tumors. PURPOSE: Phase II trial to study the effectiveness of magnetic-resonance-guided radiofrequency ablation in treating patients who have primary kidney cancer, liver metastases, or other solid tumors.
Details: OBJECTIVES: - Determine whether magnetic resonance image monitoring during radiofrequency interstitial thermal ablation can accurately predict complete destruction of focal tumor along with an adequate margin of normal tissue, as demonstrated by absence of growth on subsequent imaging studies for a 1-year period, in patients with primary renal cell carcinoma, hepatic metastases, or other solid tumors. OUTLINE: Patients are stratified according to disease (localized hepatic metastases vs primary renal neoplasms vs solid tumors in other sites). Patients undergo thermal ablation by radiofrequency energy under magnetic resonance guidance. Thermal ablation continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. Patients are followed at 2 weeks and at 3, 6, 9, and 12 months. PROJECTED ACCRUAL: A total of 28-39 patients will be accrued for this study within 22-36 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Diagnosis of primary renal cell carcinoma, hepatic metastases, or other solid tumor meeting the following criteria: - Not amenable to curative or substantial palliative therapy OR - Failed chemotherapy or biological response modifier therapy OR - Unlikely to benefit from conventional chemotherapy - No more than 5 measurable metastatic masses in the liver - No greater than 5 cm in diameter - Other tumor sites allowed if location and size amenable to ablation therapy - Measurable disease PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-2 Life expectancy: - More than 4 months Hematopoietic: - Granulocyte count at least 1,000/mm^3 - Hemoglobin at least 8.0 g/dL - Platelet count at least 100,000/mm^3 - No untreated bleeding diathesis Hepatic: - PT no greater than 13.5 seconds - PT/PTT normal if prior warfarin or heparin use Renal: - Not specified Cardiovascular: - No implanted pacemaker, incompatible aneurysm clip, or other device that would preclude magnetic resonance imaging - No myocardial infarction within the past 6 weeks - No unstable angina Other: - Not pregnant or nursing - No serious active infection PRIOR CONCURRENT THERAPY: Biologic therapy: - See Disease Characteristics - At least 28 days since prior biological response modifier therapy Chemotherapy: - See Disease Characteristics - At least 28 days since prior chemotherapy Endocrine therapy: - Not specified Radiotherapy: - No prior radiotherapy to study lesion Surgery: - Not specified Other: - At least 7 days since prior nonsteroidal antiinflammatory drugs or aspirin - At least 1 hour since prior heparin - No concurrent warfarin - No concurrent investigational drugs
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JonathanLewin, Study Chair, Ireland Cancer Center
Ireland Cancer Center *Recruiting*
Cleveland, Ohio, 44106-5065
United States
Recruiting Jonathan Lewin 216-844-8785
Additional Information:
Study ID Numbers: CDR0000068188; CWRU-2Y00,NCI-G00-1850
Study Start Date:
Record last reviewed: January 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006255
Other Unspecified Adult Solid Tumor, Protocol Specific Studies:
1. Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer
2. Epothilone B in Treating Patients With Advanced Kidney Cancer
3. Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer
4. Interferon alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
5. Chemotherapy in Treating Patients With Advanced Kidney Cancer
Related Studies:
Other unspecified adult solid tumor, protocol specific Clinical Trials
Other Ohio Clinical Trials
Other Cleveland Clinical Trials
Magnetic-Resonance-Guided Radiofrequency Ablation in Treating Patients With Primary Kidney Cancer, Liver Metastases, or Other Solid Tumors
|
|
|
|
|
|
|
|
